N'-(6-Ethoxy-1,2,3,4-tetrahydroacridin-9-yl)pyrazine-2-carbohydrazide | 1309855-85-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N'-(6-Ethoxy-1,2,3,4-tetrahydroacridin-9-yl)pyrazine-2-carbohydrazide
• CAS: 1309855-85-3
• 化学式: C₂₀H₂₁N₅O₂
• 分子量: 363.419
• InChiKey: MKRBSSQZZJBYMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  89
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  间氨基苯乙醚 在 二苯醚 、 一水合肼 、 三苯基膦 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 22.08h， 生成 N'-(6-Ethoxy-1,2,3,4-tetrahydroacridin-9-yl)pyrazine-2-carbohydrazide
  参考文献：
  名称：

  Discovery of potent nucleotide-mimicking competitive inhibitors of hepatitis C virus NS3 helicase

  摘要：

  Among the enzymes involved in the life cycle of HCV, the non-structural protein NS3, with its double function of protease and NTPase/helicase, is essential for the virus replication. Exploiting our previous knowledge in the development of nucleotide-mimicking NS3 helicase (NS3h) inhibitors endowed with key structural and electronic features necessary for an optimal ligand-enzyme interaction, we developed the tetrahydroacridinyl derivative 3a as the most potent NS3h competitive inhibitor reported to date (HCV NS3h K(i) = 20 nM). (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.09.002

文献信息

• [EN] HCV HELICASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE L'HÉLICASE DU VHC ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV KANSAS

  公开号：WO2013036749A1

  公开（公告）日：2013-03-14

  The present invention discloses thioflavine S and primuline derivatives which inhibit hepatitis C virus helicase and protease activity. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are useful as antiviral agents. The present invention further relates to pharmaceutical compositions containing the aforementioned compounds and methods of treating an HCV infection.

  本发明揭示了硫黄素S和原黄素衍生物，可抑制丙型肝炎病毒的解旋酶和蛋白酶活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并可用作抗病毒剂。本发明还涉及含有上述化合物的药物组合物和治疗HCV感染的方法。
• HCV Helicase Inhibitors and Methods of Use Thereof
  申请人：Aube Jeffrey

  公开号：US20140227225A1

  公开（公告）日：2014-08-14

  The present invention discloses thioflavine S and primuline derivatives which inhibit hepatitis C virus helicase and protease activity. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are useful as antiviral agents. The present invention further relates to pharmaceutical compositions containing the aforementioned compounds and methods of treating an HCV infection.

  本发明揭示了硫黄荧光素S和初黄素衍生物，其抑制丙型肝炎病毒的解旋酶和蛋白酶活性。因此，本发明的化合物干扰了丙型肝炎病毒的生命周期，并可用作抗病毒剂。本发明还涉及含有上述化合物的制药组合物和治疗HCV感染的方法。
• ANTI-VIRAL COMBINATION THERAPY
  申请人：KOYUNCU Emre

  公开号：US20150139949A1

  公开（公告）日：2015-05-21

  The present invention provides methods and compounds for treating viral infections using combinations modulators of an HCV-associated component and modulators of host cell enzymes. The present invention also provides methods and compounds for treating viral infections using combinations of modulators of host cell enzymes and other agents that work, at least in part by modulating hos factors.
• US9464064B2
  申请人：——

  公开号：US9464064B2

  公开（公告）日：2016-10-11
• Discovery of potent nucleotide-mimicking competitive inhibitors of hepatitis C virus NS3 helicase
  作者：Sandra Gemma、Stefania Butini、Giuseppe Campiani、Margherita Brindisi、Samantha Zanoli、Maria Pia Romano、Pierangela Tripaldi、Luisa Savini、Isabella Fiorini、Giuseppe Borrelli、Ettore Novellino、Giovanni Maga

  DOI：10.1016/j.bmcl.2010.09.002

  日期：2011.5

  Among the enzymes involved in the life cycle of HCV, the non-structural protein NS3, with its double function of protease and NTPase/helicase, is essential for the virus replication. Exploiting our previous knowledge in the development of nucleotide-mimicking NS3 helicase (NS3h) inhibitors endowed with key structural and electronic features necessary for an optimal ligand-enzyme interaction, we developed the tetrahydroacridinyl derivative 3a as the most potent NS3h competitive inhibitor reported to date (HCV NS3h K(i) = 20 nM). (C) 2010 Elsevier Ltd. All rights reserved.